[Federal Register: May 27, 2008 (Volume 73, Number 102)]
[Notices]
[Page 30418-30419]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27my08-89]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on September 21, 2007, AMRI
Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made
application by renewal to the Drug Enforcement Administration (DEA) as
a bulk manufacturer of the basic classes of controlled substances
listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360).......................... I
Tetrahydrocannabinols (7370).............. I
Amphetamine (1100)........................ II
Lisdexamfetamine (1205)................... II
Methylphenidate (1724).................... II
Pentobarbital (2270)...................... II
Hydrocodone (9193)........................ II
Meperidine (9230)......................... II
Dextropropoxyphene, bulk (non-dosage form) II
(9273)...................................
Oxymorphone (9652)........................ II
Fentanyl (9801)........................... II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers. In
reference to drug code 7360 (Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic intermediate. This controlled
substance will be further synthesized to bulk
[[Page 30419]]
manufacture a synthetic THC (7370). No other activity for this drug
code is authorized for this registration.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than July 28, 2008.
Dated: May 19, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-11633 Filed 5-23-08; 8:45 am]
BILLING CODE 4410-09-P